Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,645,116
  • Shares Outstanding, K 43,620
  • Annual Sales, $ 11,280 K
  • Annual Income, $ -83,300 K
  • 60-Month Beta 1.12
  • Price/Sales 371.76
  • Price/Cash Flow N/A
  • Price/Book 7.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.76
  • Number of Estimates 8
  • High Estimate -0.67
  • Low Estimate -0.93
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -28.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.39 +9.48%
on 01/31/20
65.88 -7.95%
on 02/19/20
-1.53 (-2.46%)
since 01/21/20
3-Month
50.87 +19.21%
on 11/22/19
76.69 -20.93%
on 01/10/20
+9.76 (+19.18%)
since 11/21/19
52-Week
36.20 +67.51%
on 10/02/19
82.49 -26.49%
on 06/20/19
+20.37 (+50.58%)
since 02/21/19

Most Recent Stories

More News
uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that seven presentations, of which one is an oral...

QURE : 60.64 (-4.64%)
uniQure to Participate in Multiple Upcoming Industry Conferences in February

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 31, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...

QURE : 60.64 (-4.64%)
BioMarin Files BLA for Gene Therapy to Treat Hemophilia A

BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

PFE : 35.72 (-0.36%)
BMRN : 95.16 (+6.13%)
QURE : 60.64 (-4.64%)
SGMO : 7.44 (-1.33%)
uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington's Disease Supporting Non-Selective HTT-Lowering Approach

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 19, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...

QURE : 60.64 (-4.64%)
uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington's Disease Supporting Non-Selective HTT-Lowering Approach

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced two publications of preclinical data from its...

QURE : 60.64 (-4.64%)
5 Biotech Stocks That Have More Than Doubled This Year

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

BMY : 65.63 (+0.71%)
MDCO : 84.90 (-0.07%)
CGEN : 10.00 (-4.85%)
QURE : 60.64 (-4.64%)
EPZM : 24.88 (-2.35%)
ACAD : 45.13 (+0.67%)
CUE : 19.81 (-4.53%)
Will uniQure Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in uniQure.

QURE : 60.64 (-4.64%)
5 Biotech Stocks Set for Continued Rally in 2020

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

XOMA : 27.66 (-3.66%)
QURE : 60.64 (-4.64%)
MRNA : 18.23 (-1.67%)
CHRS : 22.53 (+0.13%)
MGTX : 18.32 (+2.86%)
uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B

~ Sustained FIX Activity at Therapeutic Levels Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~

QURE : 60.64 (-4.64%)
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics

The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics

QURE : 60.64 (-4.64%)
BMRN : 95.16 (+6.13%)
SGMO : 7.44 (-1.33%)
SRPT : 123.98 (+0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade QURE with:

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

2nd Resistance Point 64.95
1st Resistance Point 62.80
Last Price 60.64
1st Support Level 59.43
2nd Support Level 58.21

See More

52-Week High 82.49
Fibonacci 61.8% 64.81
Last Price 60.64
Fibonacci 50% 59.35
Fibonacci 38.2% 53.88
52-Week Low 36.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar